newsfilter
← Latest News
GlobeNewswire·

Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

  • Artelo Biosciences, Inc. announced the publication of a peer-reviewed article titled "The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers" in Drug Discovery Today.
  • Dr. George Warren, Principal Scientist at Artelo, is the lead author of this review, which is the third in a trilogy exploring FABP isoforms 3, 5, & 7 in cancer biology.
  • The publication highlights evidence that FABP3 promotes tumorigenic processes through lipid metabolism, hypoxia, & ferroptosis pathways.
  • Preclinical cancer models demonstrated therapeutic benefits from both genetic & pharmacological inhibition of FABP3.
  • Artelo maintains a portfolio of selective, dual, & pan inhibitors targeting FABP3, FABP5, & FABP7 to address oncology & other indications.
  • CEO Gregory D. Gorgas stated the company plans to advance its lead program ART26.12, which targets FABP5 to treat pain, alongside broader portfolio expansion.
  • Artelo Biosciences is a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways for conditions including cancer, pain, & dermatological disorders.